raw Materials powder Prasugrel

CAS:150322-43-3

MF:C20H20FNO3S

MW:373.44

EINECS:801-962-1

Specification: 99% min Prasugrel powder

Sample:Prasugrel powder Avaliable

Packaging:1kg/bag, 25kg/drum

Brand:Ausreson

Appearance:white powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Prasugrel powder Usage and Synthesis.

Pragrel also has a stronger performance than clopidogrel in interventional surgery for stable angina pectoris and acute coronary syndrome, but the stronger the antiplatelet effect is, the more likely it is to cause bleeding. The key question now is how we can identify patients at high risk of thrombosis and how we can identify those at high risk of bleeding in the clinic, so that pragrel and clopidogrel can be used differently in the two high-risk groups, both to reduce coronary thrombosis and avoid major bleeding.

• Loading dose: A one-time higher initial dose (typically 60 mg) is given at the time of PCI to quickly achieve antiplatelet effects.
• Maintenance dose: A daily dose of 10 mg (or 5 mg for patients weighing <60 kg) is taken afterward, usually for at least 12 months (or longer, as directed by a doctor) to maintain protection, especially after stent placement.
• Timing: Taken orally, with or without food. It is rapidly absorbed, with peak effects within 30 minutes to 1 hour.

In vitro study of Prasugrel.

Prasugrel, a novel orally active thiophenyl pyridinium, has faster, higher and more reliable platelet aggregation inhibition than clopidogrel, indicating that it is metabolized in vivo as an active metabolite with selective P2Y(12) antagonistic activity.